Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Express Scripts
Moodys
Dow
Colorcon

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR CLONAZEPAM


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Clonazepam

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00025740 ↗ Clonazepam and Paroxetine for Rapid Treatment of Post-Traumatic Stress Disorder Completed National Institute of Mental Health (NIMH) Phase 4 2001-10-01 Post-Traumatic Stress Disorder (PTSD) is an anxiety disorder that follows exposure to an extremely traumatic stressors. PTSD is associated with serious symptoms. While numerous approaches have been used to treat PTSD, these treatments have several limiting factors. This study will evaluate a combination of the drugs clonazepam and paroxetine for the treatment of PTSD symptoms. The main goal of treatment in patients with PTSD is to significantly reduce symptom severity and improve functioning. While numerous approaches have been used to treat PTSD, these treatments are limited by variable response rates, up to a 6-week lag period before clinical response, and sub-optimal side effect profile, including possible worsening of anxiety and insomnia prior to clinical response. The proposed study will examine whether combined treatment with a benzodiazepine (clonazepam) and a selective serotonin reuptake inhibitor (paroxetine) in patients with PTSD will accelerate the onset of clinical response. A second goal is to evaluate whether the rapid and clinically meaningful benefits are sustained until the end of the study, despite tapering off the benzodiazepine at the midpoint of the study. The safety and tolerability of a combination of paroxetine and clonazepam will be compared to paroxetine and placebo (an inactive pill) in the treatment of PTSD. Participants in this study will be randomly assigned to receive either paroxetine plus clonazepam or paroxetine plus a placebo for 12 weeks. Participants will have weekly clinic visits for the first 4 weeks of the study and every other week for the last 8 weeks. Symptoms of PTSD, anxiety, and depression will be evaluated and drug side effects will be noted during the follow-up visits.
NCT00031317 ↗ Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression Completed National Institute of Mental Health (NIMH) Phase 4 2002-02-01 The purpose of this study is to examine the safety and effectiveness of the drug combination paroxetine and clonazepam in treating people with panic disorder (PD) and major depression. The main goal in treating people with PD is to rapidly reduce symptom severity and improve functioning. While numerous drug therapies have been used to treat PD, these treatments are limited by variable response rates and suboptimal side effect profiles. Evidence suggests that clonazepam given with a selective serotonin reuptake inhibitor (SSRI) can facilitate a rapid reduction in PD symptoms. However, it is unclear whether comorbid depression influences treatment response to the clonazepam and SSRI regimen. This study will examine whether combined treatment with clonazepam and the SSRI paroxetine will accelerate clinical response in participants with PD and comorbid depression. This study will also examine whether the benefits of treatment will be sustained until the end of the study despite tapering of clonazepam at the midpoint of the study. Participants in this study will be screened with medical and psychiatric interviews, a physical examination, electrocardiogram (ECG), and blood tests. Participants will then be randomly assigned to receive either paroxetine plus clonazepam or paroxetine plus placebo (an inactive pill) for 12 weeks. Participants will have weekly clinic visits during which symptoms and drug side effects will be checked and an interview to evaluate panic disorder and depression symptoms will be conducted.
NCT00118417 ↗ Therapies for Treatment-Resistant Panic Disorder Symptoms Completed National Institute of Mental Health (NIMH) Phase 2/Phase 3 1999-03-01 This study will determine the effectiveness of different treatments for panic disorder symptoms in individuals who still have symptoms after initial treatment with medication.
NCT00118417 ↗ Therapies for Treatment-Resistant Panic Disorder Symptoms Completed Massachusetts General Hospital Phase 2/Phase 3 1999-03-01 This study will determine the effectiveness of different treatments for panic disorder symptoms in individuals who still have symptoms after initial treatment with medication.
NCT00238914 ↗ Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 1999-08-01 The overall goal of this research project is to test a newly developed behavioral therapy to enhance the efficacy of naltrexone maintenance and make it a viable alternative to methadone maintenance or detoxification methods for treatment of opiate dependence. HYPOTHESES: 1. Outpatient treatment with Behavioral Naltrexone Therapy will yield a lower rate of relapse to illicit opiates compared to naltrexone plus Compliance Enhancement (CE) Therapy. 2. Lifetime history of depression will predict dysphoria and non-compliance with naltrexone.
NCT00238914 ↗ Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1 Completed New York State Psychiatric Institute Phase 2 1999-08-01 The overall goal of this research project is to test a newly developed behavioral therapy to enhance the efficacy of naltrexone maintenance and make it a viable alternative to methadone maintenance or detoxification methods for treatment of opiate dependence. HYPOTHESES: 1. Outpatient treatment with Behavioral Naltrexone Therapy will yield a lower rate of relapse to illicit opiates compared to naltrexone plus Compliance Enhancement (CE) Therapy. 2. Lifetime history of depression will predict dysphoria and non-compliance with naltrexone.
NCT00282828 ↗ Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder Completed National Institute of Mental Health (NIMH) Phase 4 2006-03-01 This study will compare the effectiveness of either adding clonazepam or placebo to standard treatment or switching to venlafaxine in treating generalized social anxiety disorder in individuals who have not responded to treatment with sertraline.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Clonazepam

Condition Name

Condition Name for Clonazepam
Intervention Trials
Schizophrenia 9
Burning Mouth Syndrome 6
Psychotic Disorders 5
REM Sleep Behavior Disorder 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Clonazepam
Intervention Trials
Disease 15
Mental Disorders 11
Schizophrenia 9
Syndrome 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Clonazepam

Trials by Country

Trials by Country for Clonazepam
Location Trials
United States 27
Spain 5
Korea, Republic of 4
Switzerland 4
Finland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Clonazepam
Location Trials
New York 7
Ohio 3
California 3
Massachusetts 3
Maryland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Clonazepam

Clinical Trial Phase

Clinical Trial Phase for Clonazepam
Clinical Trial Phase Trials
Phase 4 23
Phase 3 7
Phase 2/Phase 3 4
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Clonazepam
Clinical Trial Phase Trials
Completed 32
Unknown status 10
Recruiting 5
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Clonazepam

Sponsor Name

Sponsor Name for Clonazepam
Sponsor Trials
New York State Psychiatric Institute 5
Centro de Investigación Biomédica en Red de Salud Mental 5
National Institute of Mental Health (NIMH) 5
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Clonazepam
Sponsor Trials
Other 94
Industry 13
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Baxter
Express Scripts
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.